CUPERTINO, Calif., Oct. 26, 2017 /PRNewswire/ -- In conjunction
with DURECT Corporation's (Nasdaq: DRRX) third quarter 2017
financial results press release, you are invited to listen to a
conference call that will be broadcast live over the internet on
Wednesday, November 1, 2017 at
4:30 pm Eastern Time (1:30 pm Pacific Time).
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company developing therapeutics
based on its Epigenetic Regulator Program and proprietary drug
delivery platforms. DUR‑928, a new chemical entity in Phase 1
development, is the lead candidate in DURECT's Epigenetic Regulator
Program. An endogenous, orally bioavailable small molecule,
DUR-928 has been shown in preclinical studies to play an important
regulatory role in lipid homeostasis, inflammation, and cell
survival. Human applications may include acute organ injury,
chronic metabolic diseases such as nonalcoholic fatty liver disease
(NAFLD), nonalcoholic steatohepatitis (NASH) and other liver
diseases with both broad and orphan populations, and inflammatory
skin conditions such as psoriasis. DURECT's advanced oral,
injectable, and transdermal delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. One late-stage product candidate in this
category is POSIMIR® (SABER®-Bupivacaine), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery.
Another late stage product candidate is REMOXY® ER
(oxycodone), an investigational pain control drug based on DURECT's
ORADUR® technology. In addition, for the
assignment of certain patent rights, DURECT may receive a milestone
payment upon NDA approval and single digit sales-based earn-out
payments from U.S. net sales of Indivior's RBP-7000 investigational
drug for schizophrenia, for which Indivior recently submitted an
NDA. For more information, please visit www.durect.com.
NOTE: POSIMIR®, SABER®, and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
POSIMIR, REMOXY ER, RBP-7000 and DUR-928, are investigational drugs
under development and have not been approved for sale by the U.S.
Food and Drug Administration or other health authorities.
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-third-quarter-2017-earnings-conference-call-300544533.html
SOURCE DURECT Corporation